Cargando…
Inflammatory Cytokine Inhibition with Combination Daclizumab and Infliximab for Steroid Refractory Acute Graft-Versus-Host Disease
Treatment options for steroid-refractory GVHD (SR-GVHD) are unsatisfactory and prognosis is poor. Inflammatory cytokines IL-2 and TNF-α are important mediators of GVHD, and may be critical targets for therapy. We retrospectively reviewed our experience using combination anti-cytokine therapy of dacl...
Autores principales: | Rager, Alison, Frey, Noelle, Goldstein, Steven C, Reshef, Ran, Hexner, Elizabeth O, Loren, Alison, Luger, Selina M, Perl, Alexander, Tsai, Donald, Davis, Jennifer, Vozniak, Michael, Smith, Jacqueline, Stadtmauer, Edward A, Porter, David L |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3010487/ https://www.ncbi.nlm.nih.gov/pubmed/20498647 http://dx.doi.org/10.1038/bmt.2010.117 |
Ejemplares similares
-
Incidence and Predictors of Sars-Cov-2 Antibody Responses Following COVID-19 Vaccination in Allogeneic Stem Cell Transplant Recipients
por: Minehart, Janna C., et al.
Publicado: (2021) -
Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia
por: Matthews, Andrew H., et al.
Publicado: (2022) -
Pharmacodynamic effects of daclizumab in the intrathecal compartment
por: Komori, Mika, et al.
Publicado: (2017) -
Infliximab for Steroid-Refractory Immune Checkpoint Inhibitor-Induced Acute Pancreatitis
por: Townsend, Matthew J., et al.
Publicado: (2023) -
Management of pembrolizumab-induced steroid refractory mucositis with infliximab: A case report
por: Dang, Harry, et al.
Publicado: (2020)